Xtalks Life Science Podcast

Xtalks
  • 0.0（0）
  • 生命科学
  • アップデート：毎週

This Life Science focused podcast brings together Xtalks editorial staff to share insights into the latest B2B industry news. Xtalks connects professionals in the life science, medical device, and food industries with useful content like webinars, job opening, articles and virtual meetings.

  1. 2日前 ·  ビデオ

    Why Endometriosis Needs New Treatment Approaches with EndoCyclic Therapeutics’ Dr. Tanya Petrossian

    In this week’s episode of the Xtalks Life Science Podcast, host Vera Kovacevic, Editor-in-Chief at Xtalks, spoke with Dr. Tanya Petrossian, CEO and Founder of EndoCyclic Therapeutics, a biopharmaceutical company developing a non-hormonal therapeutic approach for endometriosis. Endometriosis affects many women, but it is still often difficult to diagnose, treat and fully understand. For many patients, available treatment options have historically centered on hormone-based therapies or surgery, leaving significant unmet needs in long-term care. In this episode, Dr. Petrossian discusses the patient burden of endometriosis and why the condition has remained challenging to diagnose and treat. She also shares how her own experience with delayed diagnosis helped shape her understanding of the gaps patients face and ultimately contributed to her decision to start EndoCyclic Therapeutics. The conversation explores why innovation has lagged in endometriosis, despite the condition’s significant impact on patients’ lives. Dr. Petrossian discusses the need for new treatment options, including approaches that do not rely on hormones, and explains at a high level how EndoCyclic Therapeutics’ work is designed to target disease biology. Dr. Petrossian also discusses the broader challenges and opportunities of building a company in women’s health, including the progress being made in endometriosis research and the continued need for greater recognition, investment and clinical innovation. Tune in to learn more about endometriosis, the need for new treatment approaches and what progress in women’s health innovation could look like in the years ahead. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

    28分

  2. 6月24日 ·  ビデオ

    Precision Oncology in Lung Cancer with Boehringer Ingelheim’s Itziar Canamasas and Volker Teichgräber

    In this week’s episode of the Xtalks Life Science Podcast, host Vera Kovacevic, Editor-in-Chief at Xtalks, spoke with two experts from Boehringer Ingelheim: Itziar Canamasas, PhD, Global Head of Oncology and Senior Vice President, and Volker Teichgräber, MD, Senior Vice President and Head of Global Experimental Medicine Oncology. The conversation focused on how precision oncology is changing the way advanced non-small cell lung cancer (NSCLC) is diagnosed, studied and treated. As molecular testing becomes increasingly important in lung cancer care, identifying specific genomic alterations early in the treatment journey can help inform treatment decisions and support more personalized approaches for patients. In this episode, Itziar discusses how advanced NSCLC care has evolved over the past decade and why molecular testing is central to the future of precision oncology. She also shares her perspective on the unmet needs facing patients with rare molecularly defined forms of lung cancer, including HER2-mutant NSCLC. Volker discusses the R&D considerations involved in studying rare genomic subtypes of NSCLC. He explains what researchers consider when translating early clinical findings into later-stage studies. The conversation also explores how clinical trial design is evolving in precision oncology, including the need to balance scientific rigor with the practical realities of studying rare patient groups. Itziar and Volker also discuss what may matter most for improving outcomes in advanced NSCLC and other molecularly defined cancers, from earlier testing and targeted treatment strategies to continued advances in translational medicine, biomarkers and clinical research. Tune in to learn more about precision oncology in advanced NSCLC, the role of molecular testing and the challenges of developing targeted therapies for rare genomic subtypes. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

    26分

  3. 6月10日 ·  ビデオ

    Sustainability in Asthma and COPD Drug Development with Chiesi’s Diego Ardigò

    In this week’s episode of the Xtalks Life Science Podcast, host Vera Kovacevic, Editor-in-Chief at Xtalks, spoke with Diego Ardigò, Executive Vice President, Global R&D at Chiesi, a biopharma company focused on respiratory health, rare diseases and specialty care. Respiratory medicine presents unique drug development challenges because successful therapies depend not only on the drug itself, but also on the formulation and delivery device. As innovation continues across asthma and chronic obstructive pulmonary disease (COPD), developers must balance performance, usability, sustainability and continuity of care. In this episode, Diego discusses how Chiesi approaches innovation in respiratory disease drug development and why developing inhaled therapies requires careful integration of drug formulation, device design and patient experience. The conversation also explores the growing focus on sustainability in respiratory care. Diego discusses how the industry can transition toward more environmentally sustainable inhaler options while maintaining treatment continuity for patients who are stable on their current therapies. In addition, Diego discusses the role of inhaler technique, patient behavior and long-term treatment adherence in shaping R&D decisions. Diego also explains why respiratory medicine offers valuable lessons for the broader pharmaceutical industry in balancing innovation, sustainability and patient-centered care. Tune in to learn more about the future of asthma and COPD drug development and how respiratory medicine is evolving to meet both patient and sustainability goals. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

    24分

  4. 6月4日 ·  ビデオ

    What’s Next in Cardiometabolic Disease Drug Development: Obesity, MASH and Beyond with MetaVia’s Hyung Heon Kim

    In this week’s episode of the Xtalks Life Science Podcast, host Vera Kovacevic, Editor-in-Chief at Xtalks, spoke with Hyung Heon Kim, CEO of MetaVia, a clinical-stage biotechnology company developing treatments for cardiometabolic diseases. Mr. Kim discusses the evolving cardiometabolic disease landscape, including the connections between obesity, diabetes, liver disease and cardiovascular risk. He shares his perspective on how obesity care has changed in recent years, where unmet needs remain and how priorities such as muscle preservation, metabolic health and long-term durability are shaping the next stage of drug development. The conversation also explores MASH, a complex liver disease closely linked to metabolic dysfunction. Mr. Kim discusses why MASH remains difficult to diagnose, study and treat, and why broader treatment strategies may need to address underlying drivers such as insulin resistance, inflammation and lipid metabolism. Mr. Kim also explores the challenges of designing and conducting clinical trials in obesity and MASH. He shares his perspective on where the cardiometabolic field is headed and what biotech leaders should consider when working in fast-moving, highly competitive therapeutic areas. Tune in to learn more about the future of obesity, MASH and cardiometabolic disease treatment. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

    26分

  5. 5月27日 ·  ビデオ

    How Real-World Evidence Is Shaping Inclusive Clinical Trials with Takeda CMO Dr. Awny Farajallah

    In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with Awny Farajallah, MD, Chief Medical Officer at Takeda, about the growing role of real-world evidence in improving clinical trial inclusivity and diversity. Also hear Dr. Farajallah discuss innovations in diseases such as narcolepsy type 1 and polycythemia vera, and how new technologies are transforming healthcare data into actionable insights. With over two decades of experience in the healthcare industry, Dr. Farajallah has led numerous medical affairs teams and contributed to the development and commercialization of therapeutics in oncology and other disease areas, including rare disease, hematology, neuroscience and immunology. Prior to his current role, Dr. Farajallah served as the Head of Global Medical Affairs for Oncology at Takeda, and held global, regional and local roles at Ipsen and Bristol Myers Squibb. Tune in to hear about how real-world evidence is driving more inclusive clinical trials, shaping patient-centered care and accelerating access to treatments. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

    38分

  6. 5月20日 ·  ビデオ

    Stem Cell Therapies for Degenerative Disc Disease and More with BioRestorative’s Lance Alstodt

    In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with Lance Alstodt, CEO, BioRestorative & Francisco Silva, Chief Scientist & VP, R&D, BioRestorative Inc. (NASDAQ:BRTX), a regenerative medicine company developing stem cell-based therapies and products. The company’s clinical programs target critical healthcare needs, including degenerative disc disease and metabolic disorders. Lance Alstadt has over 25 years of experience in leading medical technology and lifesciences companies in operations, capital raising activities, strategy and mergers and acquisitions. Mr. Alstodt has deep experience in the orthopedic and spine sectors. Mr. Alstodt was the Founder and CEO of MedVest Consulting Corporation an investment fund that focuses on healthcare, and previously served at Bank of America Merrill Lynch, and spent seven years in M&A at JP Morgan Chase. Mr. Alstodt has a BA in Economics from the State University of New York at Albany, with a secondary concentration in Finance and Marketing. Tune in to hear about the evolving landscape of regenerative medicine and the promise and challenges of stem cell-based therapies in treating chronic conditions like degenerative disc disease. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

    38分

  7. 5月13日 ·  ビデオ

    New Blood Test for Early Alzheimer’s Detection with FNIH’s Dr. Alessio Travaglia

    In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with Alessio Travaglia, PhD, Neuroscientist and Director of Translational Science at the Foundation for the National Institutes of Health (FNIH). New findings from a study published in Nature Medicine suggest that a single blood test may be able to predict the onset of Alzheimer’s symptoms within a three- to four-year period. Dr. Travaglia discusses how the test works, what it reveals about the earliest stages of disease and why identifying patients before symptoms appear could transform clinical trials and therapeutic development. Dr. Travaglia has 15 years of experience in basic and translational neuroscience in academia, non-profit, management consulting and venture philanthropy. Tune in to learn more about the new test and how it could transform the early detection of Alzheimer’s disease. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

    31分

  8. 5月6日 ·  ビデオ

    Targeting Ischemic Disease with DiaMedica CEO Rick Pauls

    In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke Rick Pauls, President and CEO of DiaMedica Therapeutics (Nasdaq: DMAC), a company advancing multiple programs in challenging vascular conditions driven by ischemia, including preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS). DiaMedica’s therapeutic approach in ischemia-based diseases centers on a recombinant form of the KLK1 protein, which plays a key role in regulating blood flow, reducing inflammation and supporting vascular health. Rick Pauls has served as President and CEO of DiaMedica since 2009 and has been a board member since 2005, including as Chair from 2008 to 2014. Previously, he co-founded and led CentreStone Ventures, an early-stage life sciences venture capital fund, worked as an analyst at Centara Corporation and specialized in asset-backed securitization and structured finance at General Motors Acceptance Corporation. He has also served on the boards of several public and private companies. Rick received his BA in Economics from the University of Manitoba and his MBA in Finance from the University of North Dakota. Tune in to hear about a novel therapeutic approach to treating ischemia-driven diseases like stroke and preeclampsia. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

    30分
すべて見る（258）

番組について

This Life Science focused podcast brings together Xtalks editorial staff to share insights into the latest B2B industry news. Xtalks connects professionals in the life science, medical device, and food industries with useful content like webinars, job opening, articles and virtual meetings.

情報

  • クリエイター
    Xtalks
  • 配信期間
    21年 - 26年
  • エピソード
    258
  • 制限指定
    不適切な内容を含まない
  • Copyright
    © 2024 Honeycomb Worldwide Inc.
  • 番組のWebサイト
    Xtalks Life Science Podcast

その他のおすすめ